|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Dyslexia | |||||
| 2 | More general conditions related to this trial | ||||
| Communication Disorders | |||||
| Language Disorders | |||||
| Learning Disorders | |||||
| Mental Disorders | |||||
| Mental Disorders Diagnosed in Childhood | |||||
| Nervous System Diseases | |||||
| Neurobehavioral Manifestations | |||||
| Neurologic Manifestations | |||||
| Signs and Symptoms | |||||
| 3 | Interventions listed in this trial | ||||
| Levodopa | |||||
| 4 | More general drug interventions related to this trial | ||||
| Anti-Dyskinesia Agents | |||||
| Antiparkinson Agents | |||||
| Central Nervous System Agents | |||||
| Dopamine Agents | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Neurotransmitter Agents | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Therapeutic Uses | |||||
| 5 | Sponsors listed in this trial | ||||
| University Hospital Muenster | |||||